IC4&5 Flashcards

1
Q

what are the three factors in the Virchows triad

A

1) hypercoagulability = blood
2) circulatory stasis = flow
3) vascular damage = vessel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the risk factors for hypercoagulability?

A
  • major trauma or surgery
  • pregnancy post partum
  • IBD
  • sepsis or infection
  • autoimmunity
  • malignancy
  • dehydration
  • inflmamation
  • estrogen drug therapy
  • antiphospholipid syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the risk factors for circulatory stasis?

A
  • varicose veins
  • bradycardia or hypotension
  • obstruction of venous flow = obesity, pregnancy, tumors
  • immobility
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the risk factors for vascular damage?

A
  • atherosclerosis
  • cellulitis
  • venous catheter
  • heart valves
  • physical trauma, strain, injury
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are the other risk factors for VTE?

A

age (older = more risk, esp if >75y/o)
prior history to VTE.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the symptoms of DVT?

A

UNILATERAL LL swelling, redness, pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the signs of DVT

A

1) pain behind the knee upon dorsiflexion of feet of affected limb

2) dilated superficial veins of the affected limb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the symptoms of PE? state the reasons for these symptoms

A

1) SOB, palpitations, cough, chest pain, chest tightness.

2) hemoptysis

3) dizzy, lightheaded

embolism/clot flows to the vessels at the lungs, obstructing blood flow. this reduces gaseous exchange and transport of o2 to the other parts of the body = may result in circulatory collapse.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the signs of PE?

A

1) dilated neck veins

2) tachypnoea, tachycardia, diaphoretic

3) hypotension, cyanotic, LOW SPO2

4) possible cardiogenic shock leading to death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

differential diagnosis of DVT?

A

1) cellulitis = also presents with erythema and pain

2) lymph odema, fluid retention = may present with swelling.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are the signs of hemodynamic instability in PE?

A

1) cardiac arrest

2) obstructive shock
- systolic bp <90mmhg or require vasopressors to >90mmhg
- end organ failure: cold clammy skin, altered mental status, oliguria/anuria

3) persistent hypotension
- systolic bp <90mmhg or drop of >40mmhg (last more than15min).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

differential diagnosis for PE?

A

myocardial infarction, angina?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

other classification for high-risk PE?

A

RV dysfunction on tte/ctpa and elevated troponin levels

pesi class iii-iv (includes age, hx of hf, cancer, chronic lung disease, hr, altered mental status, bp, rr, temp… etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the wells DVT scoring

A

1) active cancer
2) bedridden >3 days, major surgery last 4 weeks
3) calf diff >3cm
4) entire leg swollen
5) collateral superficial veins (non-varicose)
6) pitting edema
7) localised tenderness distributed across the deep venous system
8) paralysis or immobility of the lower limb
9) diff diagnosis that exclude = -2

more than 2 than send for imaging (CUS, compression ultrasound)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the PE wells scoring

A

1) s/sx of DVT = 3pt
2) other diff diagnosis unlikely = 3pt
3) malignancy = 1pt
4) hemoptysis = 1pt
5) bedridden >3 days, major surgent last 4 wks = 1.5 pts
6) HR >100 = 1.5pts
7) previous vte/pe = 1.5pts

if >4 points = likely diagnosis for PE = send for CTPA/VQscan.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

treatment algorithm for PE (high or mod risk)

A

if high risk:
- initiate either bolus UFH or thrombolytic therapy = weight risk vs benefit
- UFH recommended due to shorter half life = less bleeding risk esp for hemodynamically unstable patients.
- if thrombolytic therapy c/i, consider surgical pulmonary embelectomy.

if mid-low risk
- if parenteral, recommend LMWH eg enoxaparin over UFH.
- parenteral recommended due to faster onset and reliability while hospitalised (nurse administration)
if oral, recommend DOACs over VKA.

recommendation for treatment is 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

when to extend therapy for dvt/pe longer than 3 months

A

if unprovoked vte
check patient adherence
renal and hepatic impairment
weigh bleeding risk vs benefit of permanent/long term treatment

at least yearly monitoring is required eg rechecked bleeding risk

FYI conditions include medically ill eg sepsis and major surgery eg THR/TKR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

when is VKA recommended over DOACs for DVT PE

A

antiphospholipid syndrome
- should be on indefinite treatment with VKA eg warfarin

left ventricular thrombus

if patient has severe renal impairment crcl <30
- unable to use DOACs
- must be combined with UFH/LMWH that is dose adjusted for severe renal impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what happens if patient has active bleeding or current contraindication to anticoagulants

A

initiate on IVC (inferior vena cava; used to prevent the clot from travelling to lungs) filter first and start anticoagulants once bleeding is stopped or contraindication is resolved.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

when to consider LMWH monotherapy

A

1) active cancer
- treat for 6 months then reassess

2) liver disease and coagulopathy
- warfarin not suitable as iNR may not reflect antithrombotic effect.

3) pregnancy
- vka contraindicated in first trimester
- doacs not well studied

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what are the treatment algorithms for DVT

A

1) apixaban 10mg BD x 7 days > 5mg BD > 2.5mg BD
2) rivaroxaban 15mg BD x21 days > 20mg OM > 10mg OM
3) LMWH/UFH/fondaparinux x 5days then either dabigatran 150mg BD or edoxaban 60mg OD
4) LMWH/UFH/fondaparinux + PO warfarin for atleast 5 days and INR>2 (for 2 readings or 2 days in a row) THEN warfarin dose adjusted to maintain INR 2-3.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

edoxaban VTEP dose and dose modification?

A

60mg PO OD

if crcl 30-50 or BW <60kg
= 30mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

compare the renal clearance of the DOACs

A

A < R < E < D
25 33 50 80

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

compare the metabolism of DOACs

A

edoxaban is minimally hepatic, (<4% by 3a4)

dabigatran is metabolised by plasma esterases (also minimally hepatic, 80% excreted unchanged as urine)

rivaroxaban (also 2j2) and apixaban undergo cyp3a4 metabolism

ALL are affected by PGP transporters.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

(VTE) what is the renal adjustment for dabigatran?

A

crcl <50 and concomitant pop inhibitors
= avoid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

(VTE) what is the renal adjustment for apixaban?

A

15-29 caution
hd AVOID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

(VTE) what is the renal adjustment for rivaroxaban?

A

<30 avoid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

(VTE) what is the renal adjustment for edoxaban?

A

> 95 = not recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

difference between the moa of the 4 doacs

A

only dabigatran is a direct factor iia antagonist, other three are direct factor xa inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

what is the vtep dosing for dabigatran?

A

hemostasis achieved, start within 1-4h post surgery

TKR: 220mg/day x 10 days
THR: 220mg/day x 28-35days

if crcl30-50, caution, reduce to 150mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

what is the vtep dosing for rivaroxaban?

A

hemostasis achieved, start within 6-10h post surgery

TKR: 10mg/day x 2 weeks
THR: 10mg/day x 5 weeks

if medically ill, reduce dose to 10mg/day for up to 31-39 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

what is the vtep dosing for apixaban?

A

hemostasis achieved, start within 12-24h post surgery

TKR: 25mg BD x 10-14 days
THR: 25mg BD x 32-35days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

what is the vtep dosing for edoxaban?

A

30mg/day

34
Q

lab interferences of the 4 DOACs

A

derange PT/INR w/ apixaban, rivaroxaban, edoxaban

derange PTT and PT w/ dabigatran

35
Q

VTET dosing for UFH?

A

80IU/kg loading, then 18IU/kg/hr maintenance
(IV)

36
Q

VTET dosing for enoxaparin

A

1.0mg/kg Q12
OR
1.5mg/kg OD (reduce to 1.0mg/kg OD if cccl <30)

37
Q

VTEP dosing for enoxaparin

A

for surgical or medically ill:
40mg OD

THR/HFS
40mg OD or 30mg BD

for surgery = 10-14 days, up to 35 days.

crcl 30-50 for trauma patients = 30mg Q12.
crcl<30 for trauma patients = 20mg or 30mg OD.

38
Q

VTEP dosing for UFH

A

medically ill: 5000 iu q8-12 for length of stay OR until fully ambulatory

non-ortho surg no cancer: 5000iu ≥2h prior to surgery, then restart after surgery until fully ambulatory/risk of dvt low

TKR THR: 5000iu q8-12h ≥12h pre op or ≥12h post op after hemostasis achieved. (10-35 days)

39
Q

why is warfarin combined with LMWH/UFH

A

concern with hypercoagulable state due to reduction in protein c and s levels in the first few days which are responsible for anticoagulation

40
Q

why is LMWH administered on admission over DOACs or VKA

A

if suspected, LMWH has fastest onset of action as it may take awhile for imaging to be ordered.

41
Q

what are the diff types of AF and how do they differ in treatment

A

valvular AF
- mod-severe mitral valve stenosis
- presence of bioprosthetic or metallic heart valves. metallic heart valves have more thrombogenic risk
= preferred WARFARIN
(DOACs contraindicated)

non-valvular AF
- DOACs preferred

42
Q

CHA2DS2Vasc components

A

C = congestive heart failure (including ventricular dysfunction, hypertrophic cardiomyopathy)
H = hypertension
A = age (65-74; ≥75) = 2 or 1 point
D = DM
S = prior stroke history or TIA = 2 points
Vasc = vascular disease (aortic plaque, PAD, prior MI)

43
Q

weight adjustment for DOACs in SPAF

A

if <60kg, dose adjustment edoxaban and apixaban (avoid rivaroxaban and dabigatran)

if overweight >120kg OR BMI >40 , dose adjust apixaban and rivaroxaban (avoid edoxaban or dabigatran)

44
Q

how to calculate BMI

A

weight in kg / (height in m)^2

45
Q

HASBLED components

A

H: uncontrolled hypertension
A: abnormal renal (SCr > 200umol/L) or hepatic function (bilirubin >2x ULN or ALT/ALP >3x ULN)
S: stroke history
B: bleeding history
L: labile INR values, i.e., unstable, high INR, <60% TTR
E: elderly >65 or frail
D: drugs (eg nsaids) or alcohol (>14u men and >7u women per week)

46
Q

what to check during follow up sessions

A

ABC-ST

adherence: reeducate importance of adherence, do not skip dose, minor bleeding, assess cognitive function (may affect adherence)

bleeding: check for each instance of bleeding (could be more serious etiology). check whether to revise dose if bleeding affects QOL
- check risk of falling.

concomitant
= medications: OTCs? eg NSAIDs
= conditions: address uncontrolled HTN esp >160
= alcohol intake
(MODIFY RISK FACTORS)

side effects: need to stop or temporary bridging?

thromboembolism: any stroke like symptoms

47
Q

frequency of followup for DOACs (and what parameters to check)

A

check Hb, LFT, renal function test

yearly

otherwise

4 monthly: if ≥75-80y/o (esp if dabi or edox)

x monthly: if crcl <60 (crcl/10)

47
Q

what are the lab tests to conduct for VTE patients prior to starting anticoagulants?

A

1) FBC, hematocrit, platelets, Hb

2) WBC = rule out cellulitis
procalcitonin = rule out cellulitis

3) PT/INR

4) ECG (exclude AMI leading to pulmonary edema)

5) troponin (exclude MI)

6) LFT = affects production of clotting factors

47
Q

what is the dosing for dabigatran in SPAF? and dose adjustments?

A

150mg BD

110mg BD if ≥80y/o, use PGPi, HBR

CRCL
30-50 = no adj
<30 = contra (in sg)

48
Q

what is the dosing for rivaroxaban in SPAF? and dose adjustments?

A

20mg OD

CRCL
30-50: 15mg OD
15-30: caution (HSA)
<15 = contra

49
Q

what is the dosing for edoxaban in SPAF? and dose adjustments?

A

60mg OD

30mg OD if any (crcl 30-50, weight <60kg, concomitant verapamil, quinidine, dronedarone)

CRCL
30-50 = 30mg OD
<30 - no data

50
Q

what is the dosing for apixaban in SPAF? and dose adjustments?

A

5mg BD
2.5mg BD if any 2 (>80y/o, <60kg, SCr >1.5mg/dL or 132.6mmol/L

CRCL

30-50 - no adj
15-29 = 2,5mg BD
<15 = unknown.

51
Q

what drugs require dose adjustment with edoxaban (specific)

A

VERAPAMIL
QUINIDINE
DRONEDARONE

52
Q

what is the formula for CG

A

crcl = (140-age) x BW (kg) x (0.85 if female) ÷ SCr (mg/dl) x 72

if overweight = x0.4 for adjBW
can use a range with
IBW and TBW

IBW =
Men: 50 + (0.91 × [height in cm − 152.4])
Women: 45.5 + (0.91 × [height in cm − 152.4])

53
Q

which DOAC safest to give in renal impariment?

A

apixaban because it is only cleared 25% renally (least cleared renally compared to the other DOACs)

54
Q

which DOAC is a OATP substrate

A

RIVAROXABAN

55
Q

which DOAC is a BCRP substrate

A

apixaban and rivaroxaban

56
Q

examples of pgp inhibitors?

A

1) azoles
2) macrolides
3) cvs drugs: verapamil, quinidine, dronedarone, amiodarone

4) ciclosporin

57
Q

can hiv protease inhibitors be used with DOACs? what and why?

A

no

they are 3a4 inhibitors and pgp, bcrp inhibitors/inducers

e.g., ritonavir and other –navir drugs

58
Q

can otc supplements (herbal drugs) be used with DOACs? and which ones

A

green tea, ginkgo, echinacea, curcumin, ginseng…

59
Q

what are other examples of drugs to be used with caution with DOACs (excluding macrolides, azoles, antiarrythmatic drugs)

A

naproxen = pgp competition

st john worts = enzyme induction

SSRI and SNRIs = PD effect on platelets

H2RA, PPIs, antacids = affect GI absorption

60
Q

what are some special characteristics of warfarin? what genetic polymorphisms affect warfarin?

A

S enantiomer is more active
S is metabolised by CYP2C9
R is metabolised by 3A4, 1A2, 2C19, 1A1.

polymorphisms in 2c9 and VKORC1 = BOTH increases sensitivity to warfarin = reduce dose.

61
Q

how will alcohol binging affect warfarin doses

A

Alcohol binge = P450 inhibition = increase INR

decrease dose

62
Q

how will chronic alcoholism affect warfarin doses

A

Chronic alcoholism = P450 induction = increases warfarin metabolism = decrease INR.

increase dose

63
Q

how will sudden increase in phx exercise affect warfarin dose

A

Sudden increase in physical activity = increases warfarin metabolism = decrease INR.

increase dose

64
Q

how will smoking affect warfarin dose

A

Smoking = P450 induction = increases warfarin metabolism = decrease INR.

increase dose

65
Q

how does gut microbiome affect warfarin dose

A

Gut microbiome load = may require higher doses of warfarin.
o Higher gut microbiome = increased menadione (vit K derivative; involved in clotting cascade) = decreased INR.
o Use of antibiotics can disrupt gut bacteria and decrease menadione levels in the cut = more time to clot = increased INR.

66
Q

how do infections/febrile states affect warfarin dose

A

increase turnover (metabolism) of clotting factors = INR increase.

67
Q

how do fluid retention affect warfarin dose

A

o Heart failure or renal impairment may cause BOTH impaired absorption due to the oedematous gut AND liver impairment due to congestion.
o IF gut affected = malabsorption = esp in acute fluid retention = INR increases first before it drops over time (as gut malabsorption is more chronic).
o IF liver congestion > gut oedema = INR increase.

68
Q

how does liver dmg affect warfarin dose

A

Liver damage:
o Liver is involved in clotting factor production and warfarin metabolism.
o Liver impairment/damage may result in decreased clotting factor synthesis and decreased warfarin metabolism = INR increase.

69
Q

how does thyroid affect warfarin dose

A

o Hyperthyroidism increases clotting factor turnover = INR increases.

o Decreases in hypothyroidism.

70
Q

when does warfarin require preemptive dose adj for certain drugs

A

Dose adjustments required for:
o Bactrim (sulfamethoxazole & trimethoprim): 25-50% depending on reference source.
o Ciprofloxacin: 20-30% depending on reference source.
o Rifampin

No need for dose adjustments:
o Macrolides.
o Amoxiclav.
o Doxycycline.

71
Q

counselling points for warfarin?

A

no need to change your diet or avoid certain food due to its vitamin K content, as some of them such as dark green leafy vegetables contribute to a healthy diet. Keep intake consistent.

Write down the dates which you missed your dose

increase risk of bleeding and bruising. Some bleeding signs to look out for include nosebleeds, heavy menstruation, or gum bleeding. It may be necessary to switch to a soft-bristled toothbrush to reduce gum bleeding. Should you experience these side effects, please inform your doctor or pharmacist as soon as possible.

prolonged periods (more than 3 days) of fever, vomiting and/or diarrhoea, seek medical attention. Also, note down the dates and report them

72
Q

how to switch from DOAC to warfarin and vice versa?

A

if warfarin to doac , wait 3 days and INR <2 before switching
= complete reversal only in 5-7days

if doac to warfarin, can switch immediately

73
Q

what is the target inr range for mechanical heart valve? REASON?

A

2.5-3.5
high risk of thrombogenecity + likely to impose abnormal flow conditions

74
Q

what to do if there is bleeding with DOAC

A

stop meds, consider concomitant meds
- check dose and other meds
- sample crcl, WBC, LFTs

if moderate severity (non life threatening)
- consider mechanical compression
- hemostasis eg via surgical
- fluid replacement
- consider adjunct tranexamic acid (reduces fibrolysis)

if life threatening severe
- consider idarucizumab for dabi and andexanet for other 3
- consider PCC(prothrombin complex concentrates)

75
Q

how long to withhold DOAC before surgical procedure?

A

dabi:
low risk: 24-48 (increases with crcl, not indicated <30)
high risk: 48-96 (not indicated <30)

riva,edo,api:
low risk: 24 (36 if 15-30)
high risk: 48

should not use <15
consider age, stroke risk, bleeding risk any recent CVS events, renal function, comeds, comorb
consider risk level of stroke

76
Q

warfarin reversal in high risk bleeding?

A

IV vit K (if INR >1.5) and PCC (preferred)

recheck PT INR PTT 1h later and repeat as needed.

locally only iv vit k available. risk of delayed recoagulation if initiated.

77
Q

other reversal option for dabigatran?

A

consider dialysis

78
Q

other reversal options of rivaroxaban and apixaban?

A

PCC prothrombin complex concentrate